New hope for stubborn lupus: drug targets fever and inflammation
NCT ID NCT07381465
First seen Feb 02, 2026 · Last updated May 13, 2026 · Updated 9 times
Summary
This small pilot study tests a drug called firsekibart in 15 adults with mild-to-moderate lupus who did not get better with usual therapies. The drug blocks a protein (IL-1) that causes fever and inflammation. The main goal is to see if lupus symptoms improve after 12 weeks of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.